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Abstract
Background: The three members of the human heterochromatin protein 1 (HP1) family of proteins, HP1α, HP1β,
and HPγ, are involved in chromatin packing and epigenetic gene regulation. HP1α is encoded from the CBX5 gene
and is a suppressor of metastasis. CBX5 is down-regulated at the transcriptional and protein level in metastatic
compared to non-metastatic breast cancer. CBX5 shares a bi-directional promoter structure with the hnRNPA1 gene.
But whereas CBX5 expression is down-regulated in metastatic cells, hnRNAP1 expression is constant. Here, we
address the regulation of CBX5 in human breast cancer.
Methods: Transient transfection and transposon mediated integration of dual-reporter mini-genes containing the
bi-directional hnRNPA1 and CBX5 promoter was performed to investigate transcriptional regulation in breast cancer
cell lines. Bioinformatics and functional analysis were performed to characterize transcriptional events specifically
regulating CBX5 expression. TSA treatment and Chromatin Immunoprecipitation (ChIP) were performed to
investigate the chromatin structure along CBX5 in breast cancer cells. Finally, expression of hnRNPA1 and CBX5
mRNA isoforms were measured by quantitative reverse transcriptase PCR (qRT-PCR) in breast cancer tissue samples.
Results: We demonstrate that an hnRNPA1 and CBX5 bi-directional core promoter fragment does not comprise
intrinsic capacity for specific CBX5 down-regulation in metastatic cells. Characterization of transcriptional events in
the 20 kb CBX5 intron 1 revealed existence of several novel CBX5 transcripts. Two of these encode consensus HP1α
protein but used autonomous promoters in intron 1 by which HP1α expression could be de-coupled from the bi-
directional promoter. In addition, another CBX5 transcriptional isoform, STET, was discovered. This transcript includes
CBX5 exon 1 and part of intron 1 sequences but lacks inclusion of HP1α encoding exons. Inverse correlation
between STET and HP1α coding CBX5 mRNA expression was observed in breast cancer cell lines and tissue samples
from breast cancer patients.
Conclusion: We find that HP1α is down-regulated in a mechanism involving CBX5 promoter downstream
sequences and that regulation through alternative polyadenylation and splicing generates a transcript, STET, with
potential importance in carcinogenesis.
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Background
The heterochromatin protein 1 (HP1) family was first
identified in Drosophila melanogaster as essential compo-
nents of pericentric heterochromatin and shown to be
implicated in chromatin compaction and epigenetic re-
pression of gene expression [1]. In mammalian cells, the
HP1 family is composed of three distinct genes: CBX5,
CBX1, and CBX3 encoding the highly conserved proteins:
HP1α, HP1β, and HP1γ [2–5]. The HP1 proteins consist
of an N-terminal chromo domain (CD) and a structurally
similar C-terminal chromo shadow domain (CSD) sepa-
rated by a flexible hinge domain [6, 7]. The HP1 proteins
have distinct chromatin distributions with HP1α present
mainly in heterochromatin, HP1β in both hetero- and
euchromatin, and HP1γ primarily located in euchromatin
[5, 8, 9]. Tethering HP1 proteins to chromatin through
the CD, CSD or heterologous DNA-binding domains re-
sults in transcriptional repression in cis [8, 10]. The CD
mediates HP1 binding to chromatin through specific in-
teractions with di- and tri-methylated lysine 9 on the H3
histone tail (H3K9me2/3). Furthermore, the affinity for
CD binding increases proportionally with the degree of
methylation [8, 11, 12]. The CD also interacts with the tail
of linker histone H1.4 methylated on lysine 26 which par-
ticipates in further chromatin compaction [13]. The CSD
functions as a HP1 protein-protein dimerization domain
forming homo- and hetero-dimers [8, 14, 15]. The CSD
dimeric structure is also an interaction platform for
additional proteins through the core amino acid se-
quence PXVXL (X = any amino acid) [14, 15]. Many
different types of proteins containing PXVXL motifs
have been shown to interact with HP1 proteins through
the CSD [4, 5, 16–20]. However, there are proteins that
associate with the CSD of HP1 through alternative se-
quence motifs [10, 21, 22]. Notably, the CSD also inter-
acts with the first helix of the histone fold of H3 to a
PXVXL-like motif and this H3 region is involved in chro-
matin remodeling [23–26]. The hinge region of HP1 con-
tributes to chromatin association through interactions
with histone H1 and RNA. Through this interaction, RNA
components are thought to be important in the mainten-
ance and localization of HP1 proteins along specific sites
at the genome, e.g. for HP1α pericentric heterochromatin
localization [8, 27–30]. When HP1 is bound to di- or tri-
methylated H3K9 through the CD, subsequent recruit-
ment of SUV39h1 causes adjacent H3K9 residues to be-
come methylated. This creates new binding sites for
additional HP1 proteins, which, in turn, will further re-
cruit SUV39h1 proteins. This mechanism explains how
HP1 modulates the spread of heterochromatin into neigh-
boring euchromatin, a phenomenon known as position
effect variegation (PEV) [31–33]. PEV is suppressed with
decreased HP1 expression and enhanced with increased
HP1 expression [32, 33].
In breast cancer, the expression level of CBX5 and
encoded HP1α correlates with both clinical outcome in
terms of patient survival and clinical data in terms of
tumor size and stage of this disease [34]. Tumor cells
from primary breast carcinomas exhibit higher expres-
sion levels of HP1α encoding mRNA and protein com-
pared to normal breast tissue [34]. Moreover, HP1α
encoding mRNA and protein have also been shown to
be down-regulated in highly invasive breast cancer cell
lines (e.g. HS578T and MDA-MB-231) compared to
poorly invasive breast cancer cell lines (e.g. T47D and
MCF7) while HP1β and HP1γ were relative equally
expressed [20, 35–37]. Immunohistochemical analysis of
in vivo breast cancer samples showed that HP1α expres-
sion was reduced in metastatic cells relative to the pri-
mary tumor corroborating the cell line findings [36].
Following RNAi-mediated knockdown of HP1α, poorly
invasive MCF7 cells have increased invasive potential.
Conversely, highly invasive MDA-MB-231 cells loose
invasive potential following ectopic HP1α expression
[36, 38]. Based on these data, HP1α is defined as a me-
tastasis suppressor, which in contrast to tumor suppres-
sors is defined as factors being able to suppress
metastasis without affecting the growth of the tumor
[20, 36, 38, 39].
Analysis of the transcriptional regulation of CBX5 in
breast cancer cells have been performed with a resulting
mapping of cis-elements and trans-factors [40, 41].
CBX5 is orientated in a “head-to-head” bi-directional ar-
rangement with hnRNPA1. The hnRNPA1 encoded pro-
tein belongs to the A/B subfamily of heterogeneous
nuclear ribonucleoproteins involved in the packaging of
pre-mRNA into hnRNP particles, transport of poly ade-
nylated mRNA from the nucleus to the cytoplasm, and
may modulate splice site selection [42]. CBX5 and
hnRNPA1 shares a 0.6 kb promoter sequence including
binding sites for E2F and MYC-family transcription fac-
tors. Introduction of mutation in a USF/C-MYC recog-
nition site upstream for the CBX5 transcriptional start
site diminished differential expression in invasive versus
poorly invasive breast cancer cells [40]. Also, CBX5 pro-
moter binding of the transcription factor YY1 is involved
in regulating the differential expression levels in breast
cancer cells [41]. The decrease in CBX5 expression
level in metastatic breast cancer cells correlates with
decreased presence of H3K36me3, RNA polymerase II
(Pol-II), and basal transcription factors at the
promoter [37].
In this study, we find the differential expression of
CBX5 in metastatic versus non-metastatic breast cancer
cells requires a decoupling from the bi-directional pro-
moter architecture of CBX5 and hnRNPA1, and investi-
gate sequences downstream of the CBX5 promoter as
possible mediators hereof.
Vad-Nielsen et al. BMC Cancer  (2016) 16:32 Page 2 of 21
Methods
Cell lines
MCF-7 (non-invasive breast cancer cells), MDA-MB-231
(highly invasive breast cancer cells), HEMC (Primary hu-
man mammary epithelial cells) and HeLa (cervical cancer
cells) were grown in Dulbecco’s Modified Eagle’s Medium
DMEM (Lonza) supplemented with 10 % fetal bovine
serum, 1 % penicillin and 1 % glutamine. The cells were
kept in a CO2-incubator with 5 % CO2 at 37 °C. The
MCF7 and MDA-MB-231 cell lines were purchased from
American Type Culture Collection, USA and HEMC from
Life Technologies. For TSA treatment of cells 3x105
MCF7 and MDA-MB-231 cells were seeded in 6 - well
plates the day before treatment. At the day of treatment,
the media was replaced with growth media containing
1 μM TSA (Sigma) from a stock of 1 mM dissolved in a
DMSO solution of 1:3.3. As a control, separate cells where
given growth media containing the same amount of
DMSO. The cells were harvested after 24 hours. mRNA
stability in the MDA-MB-231 and MCF7 cells lines was
examined by treating cells with Actinomycin D (Sigma),
which inhibits de novo Pol-II transcription. 24 hours prior
to treatment, 5x105 cells were seeded in 25 cm2 flasks to
reach a confluence of 80 % at the time of treatment. Cells
were added fresh DMEM growth media with Actinomycin
D diluted in DMSO (1:3) to a final concentration of
10 μg/ml. Cells from one 25 cm2 flask were harvested after
0, 2, 4, 8, 12 and 24 hours, by washing twice with PBS and
scraping in 1 ml Tri Reagent™ (Sigma) and subjected to
RNA purification.
Breast cancer tissue
Breast tissue specimens were obtained from primary
breast cancer surgical procedures as described [43]. The
Regional Ethics Committee Northern Jutland, Denmark
approved the study (N-20070047), and signed informed
consent was obtained from each patient.
RNA and cDNA
RNA purification was performed using Tri Reagent™
(Sigma). The suspension was transferred to RNAse-free
eppendorf tubes and incubated for 5 minutes. 200 μl
chloroform (Merck) was added per ml Tri Reagent and
incubated for 10 minutes. After centrifugation at
12,000xg for 15 minutes at 4 °C, the upper RNA-
containing phase was transferred to RNAse-free eppen-
dorf tubes. 500 μl isopropanol (Merck) and 2 μl glycogen
(Sigma) was added followed by centrifugation at
12,000xg for 30 minutes at 4 °C. The pellet was washed
in 75 % RNAse-free ethanol and dissolved in 50 μl
DEPC H2O and stored at −20 °C. RNA concentration
was measured using a Thermo Scientific Nanodrop™
spectrophotometer. RNA integrity was confirmed by
running samples on 1 % agarose gels with added
ethidium bromide (AppliChem). For cell lines cDNA
was synthesized from 0.5 μg RNA using the BIO-RAD
iScript™ cDNA Synthesis kit containing a mix of oli-
go(dT) and random hexamer primers was used. After
synthesis the cDNA product was diluted with redistilled
water to a total volume of 100 μl and stored at −20 °C.
For breast cancer samples, cDNA was synthesized from
RNA previously isolated from primary normal breast
tissue, breast carcinomas and lymph node metastases
[43, 44]. cDNA was synthesized in a 20 μl reaction mix
including 50 μmol/L Oligo(dT), reverse transcriptase (50
units/μL), RNase inhibitors (20 units/μL), 0.4 mmol/L of
each dNTP, 1xPCR buffer, and 25 mmol/L MgCL2 (all
from Applied Biosystems Inc., CA, USA). Reverse tran-
scription was performed on the Perkin-Elmer GeneAmp
PCR System 9600 Thermal Cycler (PerkinElmer Inc.,
MA, USA) with the profile: 42 °C for 30 minutes, 99 °C
for 5 minutes and 4 °C until samples had cooled. cDNA
was stored at −20 °C until further use.
For rapid amplification of cDNA 3′-ends (3′RACE)
the first synthesis reaction utilized an oligo(dT)V primer
with anchor sequence (GCGGAATTCGGATCCCTC-
GAGTTTTTTTTTTTTTTTTTTTV*, *V denotes G, C
or A). cDNA was synthesized using 2 μg total RNA, 1 μl
oligo(dT)V primer (50 pmol), 1 μl dNTP mix 10 mM
(Qiagen), and nuclease-free water to a final volume of
13 μl. After incubation at 65 °C for 5 minutes, 4 μl First
Strand Buffer (Invitrogen) and 2 μl DTT (Invitrogen)
was added. Following incubation at 42 °C for 2 minutes,
samples were added 1 μl (15U) Superscript II Reverse
Transcriptase (Invitrogen) to a total volume of 20 μl and
further incubated at 42 °C for 50 minutes. The PCR re-
action was conducted with 5 μl of synthesized cDNA
template, 10 pmol of target cDNA forward primer
(CBX5 exon1 forward, GCAGACGTTAGCGTGAGTG)
and 10 pmol of reverse oligo(dT)-r primer (GCGG
AATTCGGATCCCTCGAGTT). A nested PCR was per-
formed using reverse oligo(dT)-r primer and a target
cDNA forward primer located downstream of the
forward primer (STET nested forward, TGTAAGCC
ACTCGAAGCCACA). PCR products of interest were
extracted after gel electrophoresis and sequenced.
Quantitative reverse transcriptase polymerase chain
reaction (RT-qPCR)
For cell lines, RT-qPCR was performed in a total reac-
tion volume of 10 μl including 1 μl cDNA, 5 μl Roche
LightCycler® 480 SYBR Green I Master enzyme (Roche),
10 pmol of both forward and reverse primer and double
distilled water up to 10 μl. A LightCycler® 480 (Roche)
was used with a PCR profile of 10 sec denaturation at
95 °C, 20 sec annealing at 95 °C and 1 min elongation at
72 °C for 50 cycles. A list of primers used in the study is
given in Additional file 1: Table S1. All primers were
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checked for amplification efficiency to be above 90 %.
Amplification efficiencies were calculated using data col-
lected from a relative standard curve, constructed by
performing serial dilutions of cDNA or purified PCR
product. The relative mRNA expression was calculated
using the X0-method, and normalized to the reference
gene GAPDH [45]. For breast cancer samples, HMBS
was used to control for variations in RNA concentration
and integrity and was found to be the best suited refer-
ence gene when compared to ACTB, GAPDH, YWHAZ
and B2M according to the Normfinder method [46].
Quantitative real-time PCR was performed using Roche
LightCycler® 480 with the settings stated above. The re-
action mix consisted of 5 μL SYBR Green I Master Mix
Buffer (Roche), 2.5 pmol forward and reverse primers
(Eurofins MWG Synthesis GmbH), 1 μL cDNA and H20
to a final volume of 10 μL. The concentration was calcu-
lated using the standard curve method. Amplicon mea-
surements outside of the range of the standard curve, or
producing an incorrect melting peak were discarded.
Morpholino and siRNA
Morpholinos were designed by Gene Tools, LLC and
transfected by the following procedure. 24 hours before
transfection 5x104 MDA-MB-231 cells were seeded in
12 well plates. A transfection media of 1 ml was pre-
pared containing 6 μl Endo-Porter (6 μM), 10 μl Mor-
pholinos (10 μM) and 984 μl DMEM growth media,
added to the cells, and incubated in a CO2 incubator at
37 °C for 48 hours. The morpholinos had the following
sequences: STET E2A1 ATCAGGAGAAAAAGATGA
TTGCCCA, STET E2A2 GGACTCCTTCCTATTAGTA
CAATGA, and Standard Control CCTCTTACCTCA
GTTACAATTTATA. STET-targeting Morpholinos were
pooled in equal amounts during preparation of transfec-
tion media. For siRNA Transfections, 100,000 MCF7
cells and 50,000 MDA-MB-231 cells were used per reac-
tion. 20 μM siRNA stocks kept at −80 °C were diluted to
2 μM with 1x Dharmacon buffer (Thermo Scientific).
25 μl siRNA was added to 25 μl DMEM (serum and
penicillin/streptomycin free) and incubated for 5 mi-
nutes. Transfection-mix was made by mixing 1 μl
Dharmafect 1 (Thermo Scientific) with 49 μl DMEM
(serum and penicillin free) per reaction and incubated
for 5 minutes at room temperature. 50 μL siRNA was
added to 50 μl transfection-mix and incubated for
20 minutes at room temperature before added to the
cells following incubation in CO2 incubator for
72 hours. Transfections were made in duplicates for
each siRNA. siRNA sequences were the following:
RRP6, CCAGUUAUACAGACCUAU; and RRP40,
CACGCACAGUACUAGGUC. As a negative control,
Non-Targeting siRNA (Thermo Scientific, Cat. No. D-
001810-10-05) was used.
Dual reporter mini-gene constructions, transfections and
genomic transpositions
Dual reporter mini-genes were constructed from the
basis of the pVP4 vector, which includes a CMV pro-
moter driven expression cassette with the β − globin
exon1-intron-exon2 fused to the EGFP encoding gene
[47]. In addition, pVP4 includes an expression cassette
for an autonomous neomycin resistance gene. By site di-
rected mutagenesis, an AscI site was inserted central in
the β − globin intron. By AseI and AscI digestion the en-
tire CMV promoter as well as the β − globin exon1 and
5′end of the intron was removed. A 1.1 kb PCR frag-
ment representing the bi-directional hnRNPA1 and
CBX5 promoter with the exon1 sequences and approxi-
mately 200 bp intron 1 sequences was inserted. The pro-
moter fragment was inserted in two different orientations




AAACCCAGCAGCATC, and Ase1-HP1α, GATCATT
AATGTCCATTCATTTCACACAATAAC and thereby
generating pCBX5-EGFP and phnRNPA1-EGFP. The vec-
tors were cut by AseI and a PCR fragment inserted
encompassing a 2 kb fragment with the 3′-end of the β −
globin intron, β − globin exon 2, and the katushka reporter
gene. This PCR fragment was generated with primers in-
cluding NdeI sites, which are compatible with AseI.
Thereby pBDf was generated that has the katushka tran-
scriptional unit under control of the hnRNPA1 promoter
and the EGFP transcriptional unit under control of the
CBX5 promoter. pBDr has the katushka transcriptional
unit under control of the CBX5 promoter and the EGFP
transcriptional unit under control of the hnRNPA1 pro-
moter. To generate a sleeping beauty transposon mini-
gene, sbBDf, the required repetitive inverted elements
were inserted to flank the katushka and EGFP transcrip-
tional units in pBDf. A 2 kb fragment representing a
continued extension of the CBX5 intron 1 present in
sbBDf was generated by PCR with primers CBX5-Intron1-
Asc1-f, ACTGGGCGCGCCCGTTATTGTGTGAAATG
AATG and CBX5-Intron1-Asc1-r, ACTGGGCGCGCCA
CTCCCTAAACATTTCAAC and cloned in the AscI site
to generate sbBDfPE. A 2 kb PCR fragment representing
the STET exon including 3′-flanking intron sequences




ACAGGAAACTA and cloned in the AscI sites of
pBDf and sbBDf to generate pBDfS and sbBDfS, re-
spectively. 24 hours before transfection 2x105 cells
were seeded in a 6 well plate. Next day, 2 μg of plas-
mid DNA, 6 μl X-treme gene 9 (Roche) and serum
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free DMEM media was mixed in a volume of 200 μl
and incubated for 30 minutes at room temperature.
The transfection mix was then added drop-wise to
the growth media of the plated cells and incubated in
CO2-incubator at 37 °C for 48 hours. For mini-gene
genomic integration by transposition, 2x105 cells were
seeded in a 6 well plate the day before transfection.
Next day, 2 μg of transposon mini-gene constructs,
200 ng of SB Puro and 200 ng of SB100 (10:1:1) were
mixed with 7.2 μl X-treme gene 9 and serum free
DMEM media in a volume of 200 μl and mixed thor-
oughly and incubated for 30 minutes at room
temperature. The transfection mix was then added
drop-wise to the growth media of the plated cells and
incubated in CO2-incubator at 37 °C for 48 hours.
The transfection media was replaced by selection
media (DMEM supplemented with 1 μg/ml puro-
mycin (Sigma)) to select for cells stably expressing
the puromycin resistance gene. Every 2–3 days cells
were washed twice with 1 ml PBS and supplied with
fresh selection media.
Chromatin immunoprecipitation (ChIP)
ChIP analyses were done essential as previously de-
scribed [37, 48]. In summary, ChIP was performed with
10 ml cultures fixed with 1 % formaldehyde for 10 min
followed by addition of glycine to 0.25 mM final concen-
tration. Cross-linked cells were washed twice with cold
PBS, scraped and lysed for 10 min at 4 °C in 1 % SDS,
50 mM Tris–HCl (pH 8.0) and 10 mM EDTA containing
protease inhibitors. Lysates were sheared by sonication
using a bioruptor (Diagenode, Liege, Belgium) to obtain
chromatin fragments <0.5 kb and centrifuged for 15 min
in a microfuge at 4 °C. 20 μg of soluble chromatin of
each sample was incubated with antibody to the follow-
ing epitopes: H3 (ab1791, Abcam, MA, USA) and
H3K9ac (ab4441, Abcam) at 4 °C for 18 h and immuno-
precipitated with a protein A and protein G magnetic
bead mix (1:1) at 4 °C for 60 min. A mock precipitation
including pre-immune polyclonal serum was included
for each ChIP experiment. After sequential washing by
the following buffers: three times with ChIP washing
buffer I (20 mM Tris–HCl, 150 mM NaCl, 2 mM EDTA,
1 % Triton X-100. 0.1 % SDS), two times with ChIP
washing buffer II (20 mM Tris–HCl, 350 mM NaCl.
2 mM EDTA, 1 % Triton X-100. 0.1 % SDS), two times
with ChIP washing buffer III (20 mM Tris–HCl,
500 mM NaCl. 2 mM EDTA, 1 % Triton X-100), the
chromatin was eluted from the beads with Elution buffer
(100 mM NaHCO3. 1 % SDS) by rotating 15 min at
room temperature. Cross-links were reversed by incuba-
tion at 65 °C for 5 to 20 h and treated with proteinase K
and RNase A. DNA was purified by phenol-chloroform
extraction and ethanol precipitation and eluted in 100 μl
TE buffer. For quantitative detection of retained DNA,
RT-qPCR were performed in triplicate and normalized
to values obtained for amplicons corresponding to
GAPDH.
Western blot and immunofluorescence
Proteins were detected in western blotting using mouse
anti-HP1α clone15.19 s2 (Millipore 05–689) in 1:1,000
dilution and rabbit anti-β −Actin (Sigma A2013) in
1:10,000 dilution. Secondary antibodies were goat anti-
mouse-HRP (Dako P0447) and goat anti-rabbit-HRP
(Dako P0448) in 1:10,000 dilutions. Western blot pro-
cedures using 75 μg protein extract in each lane were
as previously described except using Supersignal West
Dure Extended Duration Substrate (Thermo Scientific
34076) and ImageQuant LAS4000 (GE Healthcare Life
Sciences) for visualization [37]. For immunofluores-
cence experiments cells were grown in 12 well plates
on coverslips (VWR) pre-coated with Poly-L-Lysine
(Sigma) to a confluence of ~60 %. Cells were cross-
linked in 1 ml PBS containing formaldehyde (final con-
centration of 1 %) for 10 minutes at room temperature.
Crosslinking was quenched by adding 114 μl 1.25 M
glycine mixing by gentle pipetting in the well and incu-
bated further for 5 minutes at room temperature. Cells
were washed twice with 1 ml cold PBS and added 1 ml
PBS containing 0.5 % Triton X-100 and protease inhibi-
tors, and incubated for 15 minutes on ice. Cells were
again washed twice with 1 ml cold PBS and blocked by
adding 1 ml cold PBS containing 1 % BSA (Sigma) and
incubated for 1 hour on ice. Primary mouse anti-HP1α
antibody (1H5, Millipore) was diluted in PBS contain-
ing 1 % BSA of which 40 μl was placed on the bottom
of a 10 cm2 petri-dish. The coverslips were placed on
top of the 40 μl antibody with the cell side downwards.
The petri-dish was sealed and incubated on ice for
1 hour. Coverslips were transferred to a new 12 well
plate containing 1 ml cold PBS with the cell side up-
wards and washed 3x5 minutes on ice in 1 ml cold PBS.
Secondary antibodies (Invitrogen) were diluted 1:2000
in cold PBS containing 1 % BSA, of which 1 ml was
added to the coverslips after removing the PBS. The
plate was wrapped in tinfoil and incubated for 30–60
minutes on ice. Coverslips were washed 5x5 minutes in
1 ml cold PBS and wrapped in tinfoil. Nuclei were dyed
by adding 1 ml DAPI (Sigma) and incubating for 2–5
minutes at room temperature, and washed twice in
1 ml PBS. Coverslips were then dipped a few times in
double distilled water and left to air dry in a tray
wrapped in tinfoil. Coverslips were mounted on slides
by adding a drop of Prolong Gold anti-fade reagent
(Invitrogen) on the slide and transferring the coverslips
on top with the cell side downwards.
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Statistical analysis
Statistical analyses were performed using the experimen-
tal results calculated by the X0-method from triple RT-
qPCR measurements for each sample [45] or the direct
relative concentrations generated from the standard
curves in the patient sample experiments. P-values were
calculated using Students paired two-tailed t-test. Each
experiment was repeated minimum three times.
Results
HP1α down-regulation in MDA-MB-231 cells and the
CBX5 and hnRNPA1 bi-directional transcriptional unit
structure
The expression of CBX5 transcripts with coding poten-
tial for HP1α is decreased in invasive and migratory
MDA-MB-231 breast cancer cells compared to the
poorly invasive and migratory MCF-7 breast cancer cells
[20, 36, 38, 40]. The decrease in HP1α expression is
functionally linked to the enhanced invasion and migra-
tion capacity of MDA-MB-231 cells [36, 38, 40]. CBX5
has a bi-directional promoter arrangement with
hnRNAP1 (Fig. 1a). In contrast to CBX5, hnRNPA1 is
relative equally expressed in MDA-MB-231 and MCF7
cells (Fig. 1, Additional file 2: Table S2 and [37]). Thus,
expression regulation of cellular amounts of HP1α must
mechanistically be possible without associated alter-
ations in the housekeeping gene hnRNPA1. We note that
previous analyses of HP1α coding mRNA regulation
have been focused on the CBX5 promoter sequences.
However, due to the close proximity, it must be taken
into account that an element affecting the transcrip-
tional activity of CBX5 could also affect the activity of
hnRNPA1. Despite the bi-directional promoter structure,
no overall significant correlation in expression pattern is
observed between CBX5 and hnRNPA1 in the NCI-60
cancer cell line panel (correlation coefficient 0.129)
(Fig. 1b and Additional file 3: Figure S1). To investigate
the relation between CBX5 and hnRNPA1 expression,
RT-qPCR analysis in HMEC, MCF7 and MDA-MB-231
cells was performed. This showed 2.9-fold up-regulation
of CBX5 relative to hnRNPA1 in MCF7 cells versus non-
cancer breast epithelial cells (HMEC) and 0.62-fold
down-regulation in MDA-MB-231 cells relative to
HMEC (Fig. 1c). The expression analyses supported ex-
istence of independent regulation of CBX5 and
hnRNPA1 transcription in breast cancer cells with a con-
cordant up-regulation of the two genes from normal
cells to cancer cells and subsequently specific down-
regulation of CBX5 in metastatic cells (Fig. 1c). In a pre-
vious study, we showed that the CBX5 promoter is less
occupied by basal transcription factors such as TBP,
TFIIB, TFIIH as well as Pol-II in MDA-MB-231 cells
when compared to MCF7 cells [37]. The decrease in
Pol-II presence was over the entire CBX5 gene. In
contrast, histone H3 and the promoter signature marks,
tri-methylated lysine 4 (H3K4me3) and acetylated lysine
9 (H3K9ac) on the histone tail of H3, were equally
present throughout the promoter [37]. Thus, we hypoth-
esized two models facilitating differential regulation of
CBX5 and hnRNPA1 from the basis of a bi-directional
promoter. Either cis-binding of trans-regulators mediates
specific regulation in the CBX5 transcriptional orienta-
tion or presence of regulatory elements outside the bi-
directional promoter region that control transcription
specifically in the CBX5 orientation. To test this, we
constructed dual reporter mini-genes wherein the CBX5
and hnRNPA1 bi-directional promoter including both
first exons and flanking intron sequences drives bi-
directional expression of either green (EGFP) or red
(Katushka) fluorescent proteins (Fig. 1d). After transient
transfection into MCF7 and MDA-MB-231 cells, we ob-
served no preferential down-regulation of CBX5 in
MDA-MB-231 cells compared to MCF7 cells (Fig. 1d).
Flipping the promoter region relative to the marker
genes provided similar results (Fig. 1d). Thus, we con-
clude that the bi-directional promoter region per se is
not sufficient to mediate preferential CBX5 down-
regulation compared to hnRNPA1 in MDA-MB-231 cells
versus MCF7 cells.
The transient transfection approach most likely elimi-
nates detection of putative chromatin mediated effects
and can be affected by high promoter sequence copy-
number mediated titration of trans-factors. To reduce
such confounders, we constructed a sleeping beauty
based transposon mini-gene with the CBX5 and
hnRNPA1 bi-directional promoter (Fig. 1e). The mini-
gene was used to generate stable genome insertion with
sleeping beauty transposase in MCF7 and MDA-MB-231
cells. Pools of cells with genome insertions were exam-
ined for transcriptional orientation specific mRNA ex-
pression. The result again showed that the bi-directional
promoter does not have intrinsic capacity to preferential
mediate CBX5 relative to hnRNPA1 transcriptional
down-regulation in MDA-MB-231 cells versus MCF7
cells (Fig. 1e). The mini-gene lacked complete inclusion
of the two CpG islands overlapping the bi-directional
promoter and we therefore generated a mini-gene with a
2 kb intron 1 extension (Fig. 1a and e). Similar to the
CBX5 and bi-directional promoter structure, CBX3 and
hnRNPA2B1 have a 0.4 kb bi-directional promoter re-
gion, suggesting an evolutionary relationship between
the HP1 encoding genes (Additional file 3: Figure S1C).
The CBX3 and hnRNPA2B1 bi-directional transcrip-
tional unit has been carefully analyzed due to the insula-
tor capacity towards heterochromatin mediated gene
silencing in transgenic constructs by the bi-directional
promoter overlapping A2UCOE CpG island [49]. We
note that the CpG containing fragment from the CBX5
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promoter resembles the A2UCOE from CBX3 and
hnRNPA2B1, and we abbreviate the corresponding se-
quence A1UCOE. The inclusion of A1UCOE had a simi-
lar positive effect on hnRNPA1 and CBX5 transcriptional
orientations (Fig. 1e). Based on the presented expression
analyses, we conclude that the observed specific down-
regulation of the CBX5 transcriptional orientation in
MDA-MB-231 breast cancer cells, and thereby HP1α
protein, most likely is not strictly promoter dependent,
but involves promoter downstream sequences.
Deciphering novel transcripts originating from the large
intron 1 of CBX5
Inspection of CBX5 revealed existence of a large intron
1 sequence of approximately 20 kb (Fig. 1a). Intron 1 se-
quences are approximately 23 kb and 1 kb for CBX1 and
CBX3 (Additional file 3: Figure S1). In an attempt to ad-
dress the importance of the intron 1 sequence for CBX5
regulation, we checked for the presence of transcrip-
tional signatures using ENCODE data in the UCSC
browser. We note that human CBX1 and CBX3 genes
have alternative exon 1 sequences, and thereby alterna-
tive promoters (Additional file 3: Figure S1). From EN-
CODE derived data, two CBX5 signatures were evident.
One representing possible additional promoter se-
quences in the 3′-region of intron 1 and another indicat-
ing the presence of a splice form between CBX5 exon 1
and an intron 1 embedded alternatively used exon
(Fig. 2a). The latter will be described in further details
below, and we will here focus on the putative alternative
promoters in intron 1. Due to the existing nomenclature
in UCSC of various transcriptional isoforms from CBX5,
we will in the following term the HP1α protein-coding
mRNA isoform originating from the CBX5 and
hnRNPA1 bi-directional promoter for HP1α-Variant 3
(V3). The two novel potential mRNA isoforms are
termed HP1α-Variant 1 (V1) and HP1α–Variant 2 (V2)
with the latter having the most 5′-intron 1 location of
the alternative exon 1 (Fig. 2a). The ENCODE data
showed peaks of promoter mark signatures, H3K27ac
and H3K4me3, as well as the presence of Pol-II over the
alternative exon 1 sequences for HP1α-V1 and HP1α-V2
(Fig. 2a). This is in support of the presence of functional
promoter sequences. We note that HP1α-V1, HP1α-V2,
and HP1α-V3 mRNA isoforms all have coding potential
for full-length HP1α protein given that the first consen-
sus translational initiation codon resides in exon 2 for all
three transcripts (Fig. 2a). The novel HP1α encoding
transcriptional isoforms, V1 and V2, could participate in
generating relatively higher HP1α expression in non-
metastatic MCF7 breast cancer cells without require-
ment of specific CBX5 to hnRNPA1 transcriptional
enhancement from the bi-directional promoter. To ad-
dress this, we performed RT-qPCR analysis specifically
detecting each transcriptional isoform in HMEC, MCF7
and MDA-MB-231 cells. We observed similar expression
profiles for HP1α-V1 and HP1α-V2. HP1α-V3 had a dis-
tinct expression profile, which was similar to HP1α en-
coding mRNA detected by primers located in exons 4
and 5 and thereby the three isoforms altogether (HP1α-
pan) (Fig. 2b). PCR experiments showed that the HP1α-
V3 expression ratio relative to HP1α-V1 and HP1α-V2
was approximately 20-fold higher in HMEC, 3,500-fold
higher in MCF7 and 30-fold higher in MDA-MB-231
cells (Fig. 2c). Thus, expression data did not support that
HP1α-V1 and HP1α-V2 transcripts contribute signifi-
cantly to the overall HP1α encoding transcript levels in
neither MCF7 nor MDA-MB-231 cells. ENCODE data
showed the highest peak of Pol-II over the alternative
promoter sequences in HeLa cells (Fig. 2a). By RT-
qPCR, we also found that HeLa cells express HP1α-V1
and HP1α-V2 at a level comparable to HP1α-V3 (Fig. 2b
and c). Thus, the HP1α encoding V1 and V2 transcripts
might in some cellular contexts quantitatively contribute
(See figure on previous page.)
Fig. 1 hnRNPA1 and CBX5 bi-directional promoter activity in breast cancer cells. a Schematized view of the CBX5 and hnRNPA1 genes (not drawn
to scale). Arrows indicate direction of transcription. Localizations of transcription factor binding motifs in the bi-directional promoter were
obtained from [37, 40, 41]. The HP1α coding region is indicated by black colouring. pA indicates the localization of poly-A signals. A1UCOE
represents a CpG rich region homologous in localization to the characterized insulator element A2UCOE from the hnRNPA2B1 and CBX3
bi-directional promoter. b Correlation analysis of CBX5 and hnRNPA1 expression in the NCI-60 breast cancer cell panel. The analysis presented as
heat map was performed using the CellMiner database, http://discover.nci.nih.gov/cellminer/, with red symbolizing positive and blue negative
correlation. c Expression analysis of CBX5 and hnRNPA1 in HMEC, MCF7, and MDA-MB-231 cells. Relative expression was calculated from RT-qPCR
using GAPDH expression for normalization. CBX5 primers located to exon 4 and 5 and hnRNPA1 primers to exon 1 and 2. d Transient transfection
analysis of CBX5 and hnRNPA1 bi-directional promoter activity in dual reporter minigenes in MCF7 and MDA-MB-231 cells. 48 h after transfection
RT-qPCR was used to detect relative expression levels of the spliced minigene derived reporter fusion transcripts. Expression of the vector co-expressed
neomycin marker was used for normalization for transfection efficiency. Fold changes in expression ratio are shown in the right section. e Genomic
transposition analysis of the CBX5 and hnRNPA1 bi-directional promoter activity in dual reporter minigenes in MCF7 and MDA-MB-231 cells. Stable cell
lines generated by sleeping-beauty transposition of minigenes were analyzed by RT-qPCR to determine the expression levels of the spliced minigene
derived reporter fusion transcripts. Because of copy integration number differences per transposition only the ratio of expression which
was copy number independent is displayed. Fold changes in expression ratio are shown. For all panels, bars represent mean values with
standard deviations
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to the total HP1α encoding transcript levels. In conclu-
sion, the analysis of the novel HP1α-V1 and HP1α-V2
transcript isoforms were not supportive for a role dir-
ectly involved in HP1α transcript and protein down-
regulation in MDA-MB-231 compared to MCF7 cells.
We have previously shown that the H3 content over
CBX5 is equal in MCF7 and MDA-MB-231 cells, whereas
the chromatin mark coupled with transcriptional
elongation, H3K36me3, was decreased over the CBX5
gene body in MDA-MB-231 cells compared to MCF7 cells
[37]. Chromatin compaction in CBX5 intron 1 could con-
tribute to the low expression of HP1α-V1 and HP1α-V2.
To address chromatin-mediated regulation, we treated
MCF7 and MDA-MB-231 cells with the histone de-
acetylase inhibitor trichostatin-A (TSA). Previous results
have shown equal amounts of H3K9ac at the CBX5
Fig. 2 Identification of novel CBX5 generated transcripts. a Screenshot from the UCSC Genome Browser showing selected features of CBX5 and
hnRNPA1 from subtracted ENCODE datasets. On the y-axis is displayed the nature of described features. Layered H3K4me3 and H3K27ac represent
ChIP-sequence results for 7 model cell lines from ENCODE. Transcription indicates the result of RNA sequencing from 9 model cell lines from
ENCODE. MCF7, HePG2, HeLa-S3, and H1-HESC Pol-II indicates ChIP sequence results from the given cell lines. The numbering on the y-axix for
each feature indicates the quantitative measure for the RNA and ChIP sequence results. By colored boxes and the below text is indicated the
localization of the bi-directional promoter as well as intron 1 located examined alternative promoter and exon sequences. b Expression analysis
of CBX5 derived transcripts and hnRNPA1 in HMEC, MCF7, MDA-MB-231, and HeLa cells. Relative expression was calculated from RT-qPCR using
GAPDH expression for normalization. CBX5 transcript primers were specific for the indicated isoforms and HP1α-pan was detected by an exon 4
and 5 primer combination. c Expression ratio of HP1α encoding transcripts. The ratio between HP1α-V3 in relation to the sum of HP1α-V1 and
HP1α-V2 was calculated based on the data in B. For all panels, bars represent mean values with standard deviations
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promoter in MCF7 and MDA-MB-231 cells [37]. To our
surprise, we observed that in MDA-MB-231 cells TSA
treatment resulted in 5-fold decreased CBX5 expression
for all three HP1α encoding transcript isoforms (Fig. 3a).
In MCF7, no significant TSA effect was observed (Fig. 3a).
hnRNPA1 expression was 2-fold decreased following TSA
treatment and this was also observed in MCF7 cells
(Fig. 3a). We also observed HP1α protein down-regulation
by western blotting and immunofluorescence analysis
(Fig. 3b and Additional file 4: Figure S2B and S2C). ChIP
analysis showed that the H3K9ac/H3 ratio in MDA-MB-
231 cells decreased or was equal at the CBX5 and
hnRNPA1 bi-directional promoter and increased at CBX5
downstream sequences following TSA treatment (Fig. 3c).
Notably, the ChIP results for the alternative promoter re-
gions for HP1α-V1 and HP1α-V2 showed a 3-fold in-
creased level of H3K9ac, which did not correlate with
increased mRNA expression (Fig. 3c).
Identifying a novel transcript isoform, STET, originating
from alternative splicing and polyadenylation in intron 1
of CBX5
To further delineate the transcriptional structure of
CBX5 intron 1 we next focused on an embedded alterna-
tive exon indicated by transcriptional signatures using
ENCODE data in the UCSC browser. In silico a CBX5
transcript was identified consisting of exon 1 fused to
this alternative spliced and polyadenylated exon embed-
ded in intron 1 (Figs. 2a and 4a). We abbreviated this
transcript for CBX5 skipped terminal exon transcript
(STET). To verify the expression of STET, and eventual
other CBX5 intron 1 derived transcripts, we screened for
RNA expression using RT-PCR amplicons representing
different intron 1 positions (Fig. 4a). Relative to ampli-
con A4 representing the intron 1 to STET1 exon bound-
ary we observed an increase in RNA levels particularly
in MDA-MB-231 cells corresponding to amplicon A5
Fig. 3 TSA is a negative regulator of the CBX5 and hnRNPA1 locus. a TSA mediates CBX5 down-regulation. Relative expression of CBX5 derived
transcripts and hnRNPA1 in MCF7 and MDA-MB-231 cells in a TSA response after 24 h treatment. Relative expression was calculated from RT-qPCR using
GAPDH expression for normalization. CBX5 transcript primers were specific for the indicated isoforms and HP1α-pan was detected by an exon 4 and 5
primer combination. b TSA down-regulates HP1α expression at the protein level. Protein extracts were isolated from MCF7 and MDA-MB-231 cells in a
TSA response after 24 h treatment. Western blot analyses were performed with antibodies for HP1α and β − Actin for loading control using the same
membrane. c H3-K9ac and H3 ChIP analysis of the CBX5-hnRNPA1 locus. ChIP analysis were performed from MDA-MB-231 control cells or treated with
TSA for 24 h. The presented data shows the H3K9ac signal relative to H3 signal. Positions of PCR primers are indicated. The control region is located in
the un-transcribed genomic position. For all panels, bars represent mean values with standard deviations
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representing the STET 3′-UTR (Fig. 4b). Amplicons lo-
cated further downstream in intron 1 showed pro-
nounced decrease in RNA levels in accordance with a
major transcriptional stop mediated by the STET pA sig-
nal (Fig. 4b). We notice the presence of an array of 7
consensus pA signals 2 kb downstream from the STET
pA signal in the CBX5 intron 1 sequence. Downstream
of this multiple pA signal array, RNA transcript levels
approached background (Fig. 4b). However, we could
not identify transcripts terminated by the seven down-
stream pA signals by 3′-RACE. We note that down-
stream AU-rich regions can be important contributors
in co-transcriptional cleavage (CoTC). During CoTC
cleavage of the nascent transcript occurs 1–2 kb down-
stream of the polyadenylation signaling event, thereby
releasing the polymerase followed by a subsequent cleav-
age at the pA signal [50]. In conclusion, the expression
data supported the existence of significant amounts of
cellular RNA representing intron 1, including the STET
exon (Fig. 4b). Further RT-PCR analyses and sequencing
of amplicons verified the existence of STET mRNA in
both MCF7 and MDA-MB-231 cells and that two differ-
ent STET mRNAs were present (Fig. 4a-d). STET1 in-
cluded an additional extension of 32 bases in the 5′-end
compared to STET2 (Fig. 4a and c). 3′-RACE analyses
showed that the STET isoforms were polyadenylated
from an AUUAAA pA signal resulting in exon lengths
of 383 and 351 bp for STET1 and STET2, respectively
(Fig. 4c). Of additional sequence elements required for a
functional pA signal, we note the presence of an
upstream UGUA-element and downstream U-rich ele-
ments, which mediates binding of CstF-64 [51] sur-
rounding the STET AUUAAA motif (Fig. 4c). BLAST
searches identified significant STET evolutionary conser-
vation in various primates, including existence of the
two alternative splice forms of STET in e.g. marmoset,
but absence of STET in rodents. PCR experiments
showed that STET2 mRNA was more abundant than
STET1 mRNA in MCF7 and MDA-MB-231 cells
(Fig. 4d). However, whereas STET1 was 0.43-fold down-
regulated in MDA-MB-231 compared to MCF7 cells,
STET2 was 1.65-fold up-regulated (Fig. 4d). Using a pri-
mer set detecting both STET mRNA isoforms, STET-
pan, we observed that HP1α-V3 down-regulation in
MDA-MB-231 versus MCF7 cells was not linked to de-
creased STET expression supporting independent regu-
lation of the transcript levels (Fig. 4e). In contrast, TSA
treatment resulted in similar response profiles for STET
and HP1α-V3 (Figs. 4f and 3a).
Increased STET mRNA expression is not directly
functionally associated with down-regulation of HP1α
encoding mRNA
Each coupled alternative splicing and pA event resulting
in one STET mRNA could decrease the generation of
one consensus HP1α encoding transcript isoform V3
through STET exon pA mediated transcriptional termin-
ation. In a straightforward hypothesis, the increased gen-
eration of STET mRNA could mediate HP1α encoding
mRNA down-regulation in metastatic breast cancer
cells. In this case, the generation of STET transcripts
would be at the same order of magnitude as HP1α en-
coding transcripts and STET mRNA down-regulation
would follow HP1α-V3 mRNA up-regulation and vice
versa. Expression analysis, however, showed a HP1α-V3
relative to STET expression in the order of 90-fold in
MCF cells and 10-fold in MDA-MB-231 cells (Fig. 4e).
HP1α-V3 mRNA is stable and low STET mRNA stability
could lead to underestimation of the STET mRNA syn-
thesis rate [37, 41]. This was not the case as RNA stabil-
ity analysis showed an approximately similar stability of
STET mRNA and HP1α-V3 mRNA (Additional file 5:
Figure S3A). Moreover, rapid degradation of nascent
STET mRNA by the RNA exosome could decrease the
steady-state levels. siRNA mediated depletion of essen-
tial exosome components RRP6 and RRP40 influenced
(See figure on previous page.)
Fig. 4 CBX5 intron 1 generates a novel transcript STET. a Schematized view of CBX5 intron 1. Arrows indicate direction of transcription and
rectangles indicate exon sequences. The HP1α coding region is indicated by black colouring. pA indicates the localization of poly-A signals. E1 is
the first exon for HP1α-V3, E1A is the first exon for HP1α-V1, E1B is the first exon for HP1α-V2, and E2A the terminal composite exon for the STET
transcript. The two different STET transcripts, STET1 and STET2, using different splice sites are also indicated. Below the intron drawing is indicated
location of amplicons used to detect transcription throughout the CBX5 intron 1. b Scanning of CBX5 intron 1 5'-region for expressed transcripts.
Primer localizations for the various amplicons is shown in A. STET-pan indicates the measurement of the spliced STET transcript. Relative expression
was calculated from RT-qPCR using GAPDH expression for normalization. –RT threshold line in red shows the level of background calculated from
paired samples with a cDNA syntheses reaction without reverse transcriptase to account for the detection of contaminating DNA. c Nucleotide
sequence of the STET E2A and surrounding sequences. The exon sequence extension in STET1 is enclosed by rectangle. pA signal is underlined
and in bold. Different ORF’s are shown with the peptide sequences in color. d Expression analysis of STET transcripts in MCF7 and MDA-MB-231
cells. Relative expression was calculated from RT-qPCR using GAPDH expression for normalization. e Expression analysis of STET-pan in HMEC,
MCF7, MDA-MB-231, and HeLa cells. Relative expression was calculated from RT-qPCR using GAPDH expression for normalization. The calculated
semi-quantitative expression ratio between HP1α-V3 and STET is shown to the right. f TSA mediates STET transcript down-regulation. Relative
expression of STET-pan mRNA in MCF7 and MDA-MB-231 cells after 24 h TSA or DMSO control treatment. Relative expression was calculated from
RT-qPCR using GAPDH expression for normalization. For all panels, bars represent mean values with standard deviations
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HP1α-V3 mRNA and STET mRNA levels, but not in an
order of magnitude to support this mechanism to be in-
volved generating preferential low levels of STET mRNA
(Additional file 5: Figure S3B and C).
We next examined if down-regulation of STET mRNA
directly associated with HP1α-V3 mRNA up-regulation.
For this, we examined the consequences of down-
regulating STET synthesis with morpholinos corresponding
to the splice sites for the STET exon. Morpholino transfec-
tion of MDA-MB-231 cells with an equal mix of morpholi-
nos targeting either of the splice sites resulted in 5-fold
decrease in the amounts of spliced STET transcripts
(Fig. 5a). This was not accompanied by a similar alteration
in the amounts of un-spliced STET mRNA (amplicon A4)
or RNA corresponding to the downstream utilized STET
pA signal (amplicon A6) (Fig. 5a). A 0.63-fold decrease in
Fig. 5 Characterization of STET in CBX5 regulation. a Down-regulation of STET mRNA levels by morpholino transfection. MDA-MB-231 cells were
transfected with morpholino’s directed against the STET intron and exon boundary or control morpholino. Relative expression was calculated
using RT-qPCR using GAPDH expression for normalization. Neg, mock transfected cells; Mo-con, morpholino control transfected cells; and
Mo-STET, STET-specific morpholino transfected cells. b STET morpholino transfection has no significant effect on HP1α-V3 expression. MDA-MB-231
cells were transfected with morpholino’s as described in A. A4, A5, and A6 represents amplicons in CBX5 intron 1 described in Fig. 4. Relative
expression was calculated using RT-qPCR using GAPDH expression for normalization. c Transient transfection analysis of CBX5 and hnRNPA1 bi-directional
promoter activity without and with STET exon insert in dual reporter minigenes in MCF7 and MDA-MB-231 cells. 48 h after transfection RT-qPCR was used
to detect relative expression levels of the spliced minigene derived reporter fusion transcripts. Expression of the vector co-expressed neomycin marker
was used for normalization for transfection efficiency. Fold changes in expression ratio are shown in the right section. d Genomic transposition analysis of
the CBX5 and hnRNPA1 bi-directional promoter activity without and with STET exon insert in dual reporter minigenes in MCF7 and MDA-MB-231 cells.
Stable cell lines generated by sleeping-beauty transposition of minigenes were analyzed by RT-qPCR to determine the expression levels of
the spliced minigene derived reporter fusion transcripts. Because of copy integration number differences per transposition only the ratio of
expression which was copy number independent is displayed. Fold changes in expression ratio are shown. For all panels, bars represent
mean values with standard deviations
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expression was observed using an amplicon detecting both
spliced and un-spliced STET (amplicon A5) (Fig. 5b). This
was in accordance with a linkage between blocking of STET
mRNA splicing and blocking of STET pA signal usage
altogether resulting in a decrease in total STET generation.
No corresponding increase in HP1α-V3 mRNA expression
was observed un-favouring that STET mRNA generation is
directly linked with HP1α-V3 mRNA generation in a sig-
nificant amount (Fig. 5b). This cannot rule out the possibil-
ity for a stoichiometric effect such that each STET mRNA
generated is accompanied with a decreased generation of
one HP1α-V3 mRNA, but since the total amount of STET
mRNA relative to HP1α-V3 mRNA is low this will be left
undetectable. Finally, we examined how insertion of the
STET exon in a dual reporter mini-gene under transcrip-
tional control of the hnRNPA1 and CBX5 bi-directional
promoter influenced expression. For this, we used the same
expression vectors as described in Fig. 1 with the addition
of a 1.17 kb STET exon and flanking sequences insert
(Fig. 5c). Transient transfections in MCF7 and MDA-MB-
231 cells resulted in no significant decrease in the CBX5
transcriptional orientation by inclusion of the STET exon
(Fig. 5c). In cell lines with mini-gene integrations by trans-
position, we also did not detect significant STET exon me-
diated effects on the CBX5 transcriptional orientation
(Fig. 5d). In conclusion, data did not support a model
wherein STET exon sequences are mechanistically involved
in abolishing the inclusion of downstream consensus HP1α
encoding exons in quantitative amounts to mediate signifi-
cant down-regulation of HP1α-V3 mRNA expression.
Instead, the results favour that transcriptional down-
regulation of the CBX5 gene in MDA-MB-231 cells
increases the relative abundance of coupled STET exon al-
ternative splicing and polyadenylation with a resulting in-
crease in STET mRNA expression.
hnRNAP1, HP1α-V3 and STET mRNA expression during
breast cancer progression
We next analysed the relationship between hnRNPA1,
HP1α-V3 and STET mRNA expression in breast cancer
samples to see whether this corresponds to observations
from breast cancer cell lines. cDNA was prepared from
paired tissue samples from 193 patients with breast can-
cer [43, 44]. 81 of the patients had metastases in the
lymph nodes. From each patient a sample of normal
breast tissue and primary breast carcinoma were ob-
tained. From 78 of the patients a sample from the lymph
node metastases was obtained. Expression levels for
HP1α-V3, STET, and hnRNPA1 mRNA were measured
by RT-qPCR in the normal breast, primary carcinoma
samples and lymph node metastases. To acquire a nor-
mal distribution, the normalized expression values were
log-transformed and all datasets passed the D’Agastino-
Pearson normality test. Compared to normal breast
tissue samples, HP1α-V3 mRNA expression was higher
in both primary carcinoma samples from patients with
lymph node metastasis (1.75-fold, P < 0.0001) and with-
out lymph metastasis (2.02-fold, P < 0.0001) (Fig. 6b).
HP1α-V3 expression was also higher in lymph node
metastases compared to normal breast tissue (1.44-fold,
P < 0.001) (Fig. 6b). HP1α-V3 expression in the primary
carcinoma samples from patients without lymph node
metastases was significantly higher than expression in
lymph node metastases samples (1.40-fold, P < 0.01)
(Fig. 6b). Albeit not statistically significant, there was
also a tendency towards down-regulation of HP1α-V3
expression in primary carcinoma from patients with
metastases compared to lymph nodes metastases
(Fig. 6b). For hnRNPA1 mRNA we observed an in-
creased expression between normal breast tissue and
primary carcinoma samples from patients without me-
tastasis (1.33-fold, P < 0.01) (Fig. 6a). hnRNPA1 also ap-
peared upregulated in primary carcinoma samples from
patients with metastasis, but not significantly (Fig. 6a).
No difference in hnRNPA1 mRNA expression was ob-
served between primary carcinoma and lymph node me-
tastases samples (Fig. 6a). These results support the
HMEC, MCF7 and MDA-MB-231 cell line results. For
the expression ratio between HP1α-V3 and hnRNPA1,
we observed an increase between normal breast tissue
and primary carcinoma samples both from patients
without metastasis (1.46-fold, P < 0.0001) and patients
with metastasis (1.79-fold, P < 0.0001) (Fig. 6c). Also an
increase from normal breast tissue to lymph node me-
tastases was significant (1.2-fold, P < 0.05) (Fig. 6c).
Thereby, the results from the in vivo material were in
agreement with the results from cancer cell lines. No
significant difference in STET mRNA expression was
found between normal tissue and primary carcinoma
from patients with or without lymph node metastasis
(Fig. 6d). However, expression of STET was in normal
breast lower than in lymph node metastases (0.75-fold,
P < 0.05) (Fig. 6d). STET expression was also lower in
carcinomas from patients without metastasis (0.73-fold,
P < 0.05) and with metastasis (0.70-fold, P < 0.05) relative
to lymph node metastases (Fig. 6d). The HP1α-V3 to
STET ratio was significantly higher in primary carcin-
omas both from patients without metastasis (1.97-fold,
P < 0.0001) and with metastasis (1.81-fold, P < 0.0001)
relative to normal breast (Fig. 6e). The HP1α-V3 to
STET ratio was also significantly higher in primary
carcinomas both from patients without metastasis (1.76-
fold, P < 0.0001) and with metastasis (1.61-fold, P < 0.01),
compared to lymph node metastases (Fig. 6e). To
account for variation in baseline HP1α-V3 mRNA ex-
pression levels between patients, we performed an alter-
native data analysis where we normalized the expression
of HP1α-V3 and STET mRNA to the corresponding
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normal breast tissue sample (Additional file 6: Figure
S4). For the HP1α-V3 to STET mRNA expression ratio,
significant differences were observed for both primary
carcinoma samples both from patients with metastasis
(1.81-fold, P < 0.01) and without metastasis (1.68-fold, P
< 0.01) compared to lymph node metastases (Additional
file 6: Figure S4). Thus, irrespective of our data analysis
method, we identified inverse correlation between
HP1α-V3 and STET mRNA expression levels for primary
breast carcinoma versus lymph node metastases. These
findings are in alignment with the data presented for
HMEC, MCF7 and MDA-MB-231 cell lines.
Discussion
HP1α is over-expressed in several types of cancers and
the over-expression is associated with increased cell pro-
liferation most likely through silencing of cell prolifera-
tion inhibitors [34]. Moreover, HP1α has a proliferation
dependent expression level, which is reduced under
transient cell cycle exit [34]. Finally, a decrease in HP1α
Fig. 6 Expression analysis of hnRNPA1, HP1α-V3 and STET in breast cancer biopsies. a-e Based on a standard curve of serial dilutions of cDNA with
known concentrations, quantification was determined from single measurements with the second derivate max method by the LightCycler
software. Relative expression was calculated using HMBS for normalization. Results are presented as log-transformed values of HMBS normalized
data. N indicates the number of samples with measurements above limit of detection. The bars represent the mean value with surrounding
standard deviations. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. One-way ANOVA with Tukey’s multiple comparisons. For datasets with
significantly different standard deviations between means (HP1α-V3/hnRNPA1 and HP1α-V3/STET), non-parametric Kruskal-Wallis tests with Dunn’s
multiple comparisons were performed
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expression is functionally associated with an increased
invasive potential of breast cancer cells most likely due
to decreased silencing of pro-invasive genes. The Janus-
faced regulation of HP1α expression during carcinogen-
esis can be a reflection of the inverse correlation that
has been suggested between cancer cell proliferation and
invasion [34, 52]. Cancer cell metastasis requires an ac-
quisition of invasive potential and adaptation to a new
environment, which can be incompatible with a high
proliferation rate. A temporal slowdown of cell prolifera-
tion, accompanied by down-regulation of HP1α expres-
sion, can permit the expression of pro-invasive genes,
thereby resulting in metastasis [34]. However, the out-
growth of metastases requires cell proliferation and this
process can be paramount for the final patient outcome,
since high HP1α expression correlates with earlier diag-
nosis of metastasis [34]. Because of the inverse correl-
ation between HP1α expression and the invasive
potential of cancer cells, knowledge on the differential
regulation of HP1α expression is an important prospect
in fundamental cancer research [34]. In this study, we
have shown that the decrease in HP1α expression in
metastatic breast cancer cells involves promoter down-
stream sequences of the HP1α encoding CBX5 gene.
hnRNPA1 and CBX5 shares a bi-directional promoter
structure. Such “head-to-head” gene arrangements are
found at a high frequency throughout the human gen-
ome with ~11 % of all genes defined as bi-directional
promoter genes by being divergently transcribed, and
with transcriptional start sites (TSS) less than 1 kb away
from each other [53–55]. Bi-directional arrangements
are often evolutionary conserved, indicating functional
importance of this specific gene structural modulation
[56–58]. In this line, expression of bi-directional pro-
moter genes are more correlated than those of randomly
selected and neighboring genes. This is exemplified by
gene pairs needed in stoichiometric amounts e.g. histone
genes, functioning in the same biological pathway e.g.
DNA repair, and co-expressed at specific time points
during cycle or in response to induction signals e.g. heat
shock [54, 59]. Bi-directional promoter sequences share
several features separating them from the general non-
bi-directional promoters [58]. Bi-directional promoters
are more often located within a CpG island (77 %)
compared to non-bi-directional promoters (38 %) and
bi-directional promoters have a GC-content (66 %),
which is higher than non-bi-directional promoters
(53 %) [56–58]. Furthermore, the relative presence of
canonical TATA box elements is significantly less for bi-
directional promoters (8 %) compared to other pro-
moters (28 %) [54, 60]. Bi-directional promoters display
an enriched occurrence of specific transcription factor
binding sites, including GABPA, MYC, E2F, NRF and
YY1 [59]. These cis-elements are often functionally
shared for both transcriptional directions [54, 61]. The
hnRNPA1 and CBX5 bi-directional promoter lacks
TATA box elements, contains a CpG island, and in-
cludes binding motifs for signature bi-directional pro-
moter transcription factors e.g. YY1, E2F and MYC, and
thus is a consensus representative of bi-directional pro-
moters [37, 40, 41, 62, 63]. We identified no significant
correlated expression pattern between hnRNPA1 and
CBX5 in the NCI-60 cancer cell panel. This is illustrated
by the CBX5 down-regulation in metastatic breast can-
cer cells compared to poorly invasive breast cancer cell
lines whereas hnRNPA1 is relatively evenly expressed in
both types of cell lines [36, 37, 40, 41]. However, we note
that from normal breast epithelial cells to MCF7 cells
both hnRNPA1 and CBX5 are up-regulated. The sce-
nario is different for the CBX3 and hnRNPA2B1 bi-
directional promoter that results in a highly correlated
expression of these two genes in the NCI-60 cancer cell
panel including MCF7 and MDA-MB-231 cells. Thus,
for hnRNPA1 and CBX5 evolution must have adapted
regulatory mechanisms un-coupling the expression of
the two genes under certain cellular environments e.g.
during breast cancer metastasis. Going from an in vitro
breast cancer cell model using HMEC, MCF7 and
MDA-MB-231 cells to clinical breast cancer samples, we
could largely replicate findings concerning the up-
regulation of both hnRNPA1 and CBX5 in carcinoma
versus normal breast epithelial cells, de-coupling of
hnRNAP1 and CBX5 expression in metastatic breast
cancer cells, and the relative up-regulation of the STET
transcript in metastatic breast cancer cells. This validates
that in this case our cell line based model is valuable for
investigating in vivo breast cancer progression.
Previous studies have focused on human CBX5 regula-
tion in terms of cis-elements and transcription factor
binding to the consensus promoter region upstream and
in exon 1. This resulted in the identification of a USF/C-
MYC recognition site upstream for the CBX5 transcrip-
tional start site to be involved mediating differential ex-
pression in invasive versus poorly invasive breast cancer
cells [40]. Based on observations in both transient and
genome integrated reporter systems, our presented ana-
lyses point to importance of also promoter downstream
transcriptional regulatory events. We observed that the
isolated hnRNPA1 and CBX5 bi-directional promoter
shows no significant preference for CBX5 relative to
hnRNPA1 down-regulation in MDA-MB-231 cells. One
hint of a transcriptional regulatory mechanism for CBX5
beyond promoter mediated initiation comes from a re-
cent study of transcriptional pausing [64]. The majority
of human genes are at the promoter proximal region
loaded with paused Pol-II poised for release by the posi-
tive elongation factor pTEFb into productive elongation.
Gdown1 was shown to be a sub-stoichiometric subunit
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of Pol-II complex. Gdown1 inhibits termination of Pol II
by TTF2 thereby preventing release of short transcripts
and Pol-II dissociation, blocking elongation stimulation
by TFIIF and influencing pausing factors NEFL and
DSIF. The hnRNPA1 and CBX5 promoters are both as-
sociated with Gdown1 and poised Pol-II [64]. Notably,
two such Pol-II and Gdown1 peaks are present at CBX5
50 and 450 bp downstream of the bi-directional pro-
moter [64]. Since binding of Gdown1 to the promoter is
linked with efficient transcriptional elongation and pro-
moting stability of the paused Pol-II complex, deficiency
in Gdown1 functional association to the bi-directional
promoter in MDA-MB-231 cells could be a theoretical
possibility. Thus, a skewed expression pattern in favor of
hnRNPA1 expression relative to CBX5 expression will be
obtainable, given the Gdown1 effect is directed specific-
ally towards CBX5 in a yet not proven mechanism. This
scenario is in line with our previous observation of less
abundance of the transcriptional elongation chromatin
mark H3K36me3 in MDA-MB-231 cells [37, 65]. Im-
portantly, we observed that throughout the CBX5 gene,
with the exception of the STET transcript to be discussed
below, lesser amounts of transcripts were present in
MDA-MB-231 cells compared to MCF7 cells. We have
described that in MDA-MB-231 cells less Pol-II was
present at the promoter compared to MCF7 cells [37]. We
note that Gdown1 is equally expressed in MCF7 and
MDA-MB-231 cells (Additional file 2: Table S2).
Another possibility in breast cancer cells to mechanis-
tically disconnect generation of HP1α from the function-
ally shared promoter architecture for CBX5 and
hnRNPA1 is the use of downstream alternative pro-
moters producing HP1α coding transcripts. We identi-
fied two such alternative promoters in the CBX5 intron
1 resulting in two additional HP1α encoding transcripts,
HP1α-V1 and HP1α-V2. Both transcripts contain the en-
tire full-length HP1α coding region, but with an alterna-
tive first exon not included in the canonical HP1α
encoding transcript, HP1α-V3. However, in the cancer
cell lines the quantitative significant production of HP1α
was concluded to be restricted to transcripts produced
from the bi-directional promoter. In HMEC, MCF7 and
MDA-MB-231 cells we observed an inverse expression
pattern of HP1α-V3 compared to HP1α-V1 and HP1α-
V2. This could be a consequence of transcriptional inter-
ference where high transcriptional rate dictated from the
bi-directional promoter repressed activity of the down-
stream alternative promoters. It should not be ruled out
that the alternative CBX5 promoters e.g. in certain cell
or tissue types or during cell cycle or developmental
stages, could contribute significantly to HP1α expres-
sion. In line with this, we note that we in HeLa cells ob-
served a significant contribution of theses alternative
transcripts to the total content of HP1α encoding
mRNA. Recently, an alternative downstream promoter
for generating HP1α encoding mRNA was described in
mice and the significance can be based upon a high de-
gree of sequence conservation in mammalians of the
genomic region corresponding to the alternative pro-
moters [66]. Surprisingly, we observed after TSA treat-
ment of MDA-MB-231 cells a coordinated and strong
down-regulation of HP1α-V3, HP1α-V1, HP1α-V2, and
STET transcripts as well as down-regulation of HP1α
protein expression. hnRNPA1 was also down-regulated
but to a lesser extent. In MCF7 cells hnRNPA1 was re-
pressed by TSA in magnitude similar to MDA-MB-231
cells whereas CBX5 transcripts displayed only a minor
and non-coordinated response. MDA-MB-231 ChIP ex-
periments showed no TSA induced increase in levels of
acetylated histone H3 at the bi-directional promoter re-
gion. Repression of the CBX5-hnRNPA1 locus could be
mediated through recruitment of a TSA induced trans-
repressor. However, we note that the TSA induced de-
crease of the CBX5 transcripts in MDA-MB-231 cells
was more pronounced than could expected for only an
effect on transcription given the relative high mRNA sta-
bility (Additional file 5: Figure S3 and [37]). This could
indicate TSA induced de-stabilization of CBX5 tran-
scripts, similar to e.g. claudin-1 mRNA [67].
Bioinformatics analysis, as well as analysis of the
mouse CBX5 gene, revealed presence of several evolu-
tionary conserved regions and transcribed regions in
CBX5 intron 1 [66]. Our further investigation of one
such region led to the identification of two novel tran-
scripts from CBX5 termed STET1 and STET2. These are
transcribed from the same promoter as HP1α-V3 mRNA
and thereby contain exon 1 which is now spliced to an
intron 1 embedded alternative exon located ~5 kb
downstream of the TSS. The alternative STET exon in-
cludes a functional pA signal. STET mRNA generation
thereby constitute an alternative cleavage and polyade-
nylation (APA) event and the STET exon E2A classifies
as a composite terminal exon. Studies analyzing APA
events have mainly been focused on the 3′-UTR, but
RNA-sequence analysis have revealed that 20 % of hu-
man genes have at least one intronic APA event and that
the APA events can be developmental and cell cycle reg-
ulated to regulate expression [68–70]. We note that E2F
transcription factors were described to enhance alter-
native intronic polyadenylation in a cell proliferative
dependent manner and the presence of a E2F cis-elem-
ent in the bi-directional promoter could provide a link
to STET mRNA generation [71]. Mechanistic selection
of STET alternative splicing and polyadenylation is ex-
pected in stoichiometric amounts to decrease the gener-
ation of HP1α-V3 transcripts with HP1α encoding
potential. Given that STET is relatively more expressed
in MDA-MB-231 cells compared to MCF7 cells this
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opens an appealing model for the specific CBX5 relative
to hnRNPA1 down-regulation in MDA-MB-231 cells.
This will however require that STET mRNA generation
in quantitative amounts is comparable with HP1α en-
coding mRNA. Since our analyses systematically identi-
fied STET mRNA in minor amounts compared to HP1α
encoding mRNA, we have no supportive evidence for
such a regulatory model. Furthermore, insertion of the
STET composite terminal exon in a mini-gene back-
ground had neither in transient nor genome integrated
analysis a negative influence for the inclusion of a STET
exon downstream located exon. Finally, despite that we
find the bi-directional promoter equally transcriptional
prone in MCF7 and MDA-MB-231 cells, we also ob-
served less exon 1 included transcripts and less Pol-II,
TBP, TFIIB, and TFIIH loading on the canonical CBX5
promoter in MDA-MB-231 cells indicating less tran-
scription [37]. It is important to notice that histone H3
as well as H3K9ac and H3K4me3 occupancy over the
CBX5 promoter was similar in the two cell lines pointing
that the chromatin structure per se is not inhibitory in
MDA-MB-231 cells [37]. Thereby, the current results
could fit a model wherein reduced CBX5 transcriptional
quality in metastatic breast cancer cells mediated by
downstream elements e.g. through impaired transcrip-
tional re-initiation and elongation, results in relative in-
creased inclusion of the STET composite exon.
History has dictated genes to be perceived as linear
entities confined by promoters and terminators that de-
termine where transcription starts and ends. Studies
concerning the regulation of HP1α have hence mainly
been restricted to the canonical CBX5 promoter region.
However, our presented results for the differentially
expressed CBX5 mRNA and the constitutively expressed
hnRNPA1 mRNA have indicated novel mechanisms
associated with regulation of HP1α expression through
sequences located downstream the bi-directional pro-
moter. The present study highlights the need for
additional focus on the transcriptional regulatory mech-
anistic backgrounds for deregulated HP1α expression
under development and metastatic progression of breast
cancer.
Conclusion
In this study, we demonstrate that an hnRNPA1 and
CBX5 bi-directional core promoter fragment shows no
significant preference for CBX5 relative to hnRNPA1
down-regulation in metastatic MDA-MB-231 cells.
Thus, we conclude that the bi-directional promoter re-
gion per se is not sufficient to mediate preferential CBX5
down-regulation compared to hnRNPA1 in MDA-MB-
231 cells versus MCF7 cells, but involve sequences
located downstream the canonical CBX5 promoter.
Characterization of transcriptional events in the CBX5
20 kb long intron 1 revealed existence of several novel
CBX5 transcripts. Two of these encoded consensus
HP1α protein but used autonomous promoters located
within intron 1 by which HP1α expression could be de-
coupled from the bi-directional promoter. However, in
breast cancer cell lines a quantitative significant produc-
tion of HP1α was concluded to be restricted to tran-
scripts with origin from the bi-directional promoter. In
addition, a novel CBX5 transcriptional isoform, STET,
was discovered. This transcript includes CBX5 exon 1
and part of intron 1 sequences through alternative spli-
cing and polyadenylation, but lacks inclusion of HP1α
encoding exons. Inverse correlation between STET and
HP1α coding mRNA expression, transcribed from the
canonical CBX5 bi-directional promoter was observed in
both breast cancer cell lines and samples from breast
cancer patients. Mechanistic selection of STET alterna-
tive splicing and polyadenylation is expected in stoichio-
metric amounts to decrease the generation of CBX5
transcripts with HP1α encoding potential. This could
thereby comprise a novel mechanism of HP1α encoding
mRNA regulation. However, we systematically identified
STET mRNA in minor amounts compared to HP1α en-
coding mRNA. Moreover, insertion of the STET compos-
ite terminal exon in a mini-gene background had neither
in transient nor genome integrated analysis a negative
influence for the inclusion of a STET exon downstream
located exon. Thus, we have no supportive evidence for
such a regulatory model. Therefore, the results more
likely reflects a model wherein reduced CBX5 transcrip-
tional quality mediated by promoter downstream mech-
anisms e.g. through impaired transcriptional re-initiation
and elongation, results in relative increased inclusion of
the STET composite exon.
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Additional file 1: Table S1. Sequences for primers used in RT-qPCR.
(DOCX 17 kb)
Additional file 2: Table S2. Expression data extracted from Affymetrix
microarray experiments. (DOCX 17 kb)
Additional file 3: Figure S1. CBX1 and CBX3 and correlation of
expression analyses. A) Schematized view of CBX3 and hnRNPA2B1 (not
drawn to scale). Arrows indicate direction of transcription. The coding
region is indicated by black colouring. pA indicates the localization of
poly-A signals. A2UCOE represents localization of the characterized
insulator element. B) Correlation analysis of CBX3 and hnRNPA2B1
expression in the NCI-60 breast cancer cell panel. The analysis presented
as heat map was performed using the CellMiner database, http://
discover.nci.nih.gov/cellminer/, with red symbolizing positive and blue
negative correlation. C) Correlation analysis of CBX1, CBX3, CBX5, hnRNPA1
and hnRNPA2B1 expression in the NCI-60 breast cancer cell panel. The
analysis presented as correlation coefficients estimated using the
CellMiner database with red numbering symbolizing significant
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expression correlation. D) Schematized view of CBX1 and neighboring
SNX11 (not drawn to scale). Arrows indicate direction of transcription. The
coding region is indicated by black coloring. The position of a promoter
overlapping CpG island is shown. (PDF 380 kb)
Additional file 4: Figure S2. TSA effects on CBX1, CBX3 and CBX5
expression. A) mRNA expression analysis of the CBX1, CBX3 and CBX5
response towards TSA. Relative expression levels of CBX mRNA in MCF7
and MDA-MB-231 cells after 24 h treatment with TSA or control DMSO.
Relative expression was calculated from RT-qPCR using GAPDH expression
for normalization. For all panels, bars represent mean values with
standard deviations. B) Immunofluorescence analysis of HP1α (upper
panels) or DAPI staining in MDA-MB-231 cells either untreated or TSA
treated for 24 h. C) Zooming in on a representative immunofluorescence
analysis of HP1α in MDA-MB-231 cells with arrows pointing on
heterochromatic spots. (PDF 914 kb)
Additional file 5: Figure S3. RNA stability analysis of HP1α-V3 and STET.
A-B) mRNA decay analysis of HP1α-V3, STET and C-MYC following
Actinomycin D treatment in MCF7 (A) and MDA-MB-231 cells (B). Cells
were treated with Actinomycin D and harvested at indicated time points.
Relative expression was calculated from RT-qPCR using GAPDH expression
for normalization. C) Knockdown efficiency of siRNA mediated
knockdown of RRP6 and RRP40 mRNA in MCF7 and MDA-MB-231 cells,
respectively. Expression of HP1α-V3, STET and amplicon A1 RNA after RRP6
and RRP40 siRNA mediated knockdown in MCF7 and MDA-MB-231 cells,
respectively. Relative expression was calculated from RT-qPCR using
GAPDH expression for normalization. For all panels, bars represent mean
values with standard deviations. (PDF 574 kb)
Additional file 6: Figure S4. Expression analysis of hnRNPA1, HP1α-V3
and STET in breast cancer biopsies normalized to normal breast biopsies.
A-E) Based on a standard curve of serial dilutions of cDNA with known
concentrations, quantification was determined from single measurements
with the second derivate max method by the LightCycler software.
Relative expression was calculated using HMBS for normalization. To
correct for diversity of baseline expression between patients, expression
of each carcinoma sample was further normalized to the corresponding
normal breast tissue sample of that patient. Results are presented as log-
transformed values of HMBS and normal breast tissue normalized data. N
indicates the number of samples with measurements above limit of
detection. For all panels, bars represent mean values with standard
deviations. ** P < 0.01; one-way ANOVA with Tukey’s multiple comparison.
For datasets with significantly different standard deviations between
means non-parametric Kruskal-Wallis test with Dunn’s multiple
comparison was performed. (PDF 333 kb)
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